Print Page      Close Window     

Investors

SEC Filings

6-K
OBSEVA SA filed this Form 6-K on 03/30/2018
Entire Document
 


LOGO

 

OBE2109 potential best in class based upon PK/PD profile     OBE2109 ELAGOLIX*RELUGOLIX* Half-Life14-15 hours2-6 hours37-42 hours Bioavailability> 80%30 – 50 %11% Active transport limitingNoInhibitor & Saturable substrate Substrate absorption (P-gP) Volume of distribution11 L>2,000 L>20,000 L (unadjusted for bioavailability) Partition into fatNoYesYes Food Effect NoYesYes CYP3A4 induction (possible NoYesNo adverse impact on ABT)